On March 4, 2008, Perrigo announced that it began shipping 20 mg Omeprazole delayed released tablets to its retail customers. This product delivers the same medicine at the same dose as Prilosec OTC(R) and is indicated for the treatment of frequent heartburn.
For the first nine months of fiscal 2008, Consumer Healthcare net sales were $961.5 million, up $181.5 million, or 23 percent, compared with $780.0 million last year. The sales gain was driven by new product sales of $117 million, largely Omeprazole, Cetirizine and Smoking Cessation products. Reported operating income was $120.5 million, compared with $56.8 million a year ago. Adjusted operating income was $123.8 million, compared with adjusted operating income of $57.7 million last year.
The Rx Pharmaceutical segment reported third quarter net sales of $49.2 million, including $3.1 million of service and royalty revenue and an $8.5 million payment for termination of a license agreement. This represents an increase of $15.2 million, or 45 percent, compared with $34.0 million last year, of which $5.8 million was service and royalty revenue. Operating income was $11.3 million, up from $7.6 million a year ago, as a result of increased volume and improved margins.
For the first nine months of fiscal 2008, net sales were $122.8
million, including $11.9 million of service and royalty revenue and an $8.5
million payment for termination of a license agreement, resulting in an
increase of $29.1 million, or 31 percent, compared with $93.7 million last
year, of which $15.8 million was service and royalty revenue. Operating
income was $27.2 million, up $10.2 million, or 60 percent,
|SOURCE Perrigo Company|
Copyright©2008 PR Newswire.
All rights reserved